SCHEMBL5111520

SCHEMBL5111520

NC(=O)n1c[c]c(-c2nc3c(=O)n(Cc4ccccc4)ncc3[nH]2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.37
DGAT1 O75907 4/20 0.35
AURKA O14965 1/20 0.35
KDR P35968 1/20 0.35
AURKB Q96GD4 1/20 0.35
ALDH1A1 P00352 3/20 0.34
LMNA P02545 3/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 2/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
RAF1 P04049 1/20 0.33
DHODH Q02127 1/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
RAB9A P51151 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5111527 0.71 MAPT (0.39) HSD17B10ALDH1A1LMNAMAPTKDM4E
SCHEMBL8273298 0.71 HSD17B10 (0.51) HSD17B10ALDH1A1LMNAMAPTKDM4E
SCHEMBL4891866 0.61 PDE4A (0.52) AURKAAURKB
SCHEMBL22989952 0.59 MAPT (0.71) HSD17B10AURKAALDH1A1LMNAMAPT
SCHEMBL9027681 0.58 TDP1 (0.72) HSD17B10ALDH1A1LMNAMAPTKDM4E
SCHEMBL29703247 0.58 TDP1 (0.72) HSD17B10ALDH1A1LMNAMAPTKDM4E
SCHEMBL22989951 0.58 MAPT (0.48) HSD17B10ALDH1A1LMNAMAPTKDM4E
SCHEMBL1244057 0.58 HSD17B10 (0.49) HSD17B10ALDH1A1MAPTKDM4ETSHR
SCHEMBL13911130 0.58 ALDH1A1 (0.42) HSD17B10ALDH1A1LMNAMAPTKDM4E
SCHEMBL4799238 0.57 ALDH1A1 (0.52) HSD17B10ALDH1A1LMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
EP-1781653-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors CDK3, CDK1, GSK3B HSD17B10 1196/4885DGAT1 3712/4885AURKA 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.